NBI-98854 (Neurocrine Biosciences) moves into Phase IIb for Tardive Dyskinesia

NeuroCrine Biosciences has announced efficacy and safety results from a Phase II trial of NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, data from one site was removed due to the inconsistent and incorrect application of the efficacy assessment protocol. With this site removed, the results showed a significant reduction in tardive dyskinesia symptoms at end of two weeks of active treatment with 50mg once-daily doses of NBI-98854. The company plans to begin a placebo controlled, double-blind, parallel-design, multiple-dose, twelve-week Phase IIb study in mid-2012.